English
Czech
Danish
Dutch
French
German
Hungarian
Italian
Portuguese
Russian
SpanishDr. A.S. Fauci Corrects Previous Statement Regarding COVID-19 Vaccines & GBS
As a follow up to the Foundation’s published article from Dec. 20, 2020, “An Open Letter to Dr. A.S. Fauci, Director NIAID, NIH,” on January 15, 2021, Neurology Today published the following article “No Excess Risk for Neurologic Events Observed to Date from COVID-19 Vaccines.” Read the full article…
DIY Fundraising in a Virtual World
DIY Fundraising Event COVID-19 has caused all of us to rethink how we get together and socialize with our family and friends. Are you looking for ways to cure your post-holiday blues while making a difference in the GBS│CIDP patient community? We have brainstormed some creative ways you can host a DIY fundraising event in…
Persons who have previously had GBS may receive an mRNA COVID-19 vaccine
Adults of any age with certain underlying medical conditions are at increased risk for severe illness from the virus that causes COVID-19. mRNA COVID-19 vaccines may be administered to people with underlying medical conditions provided they have not had a severe allergic reaction to any of the ingredients in the vaccine. The following information aims to help people in the…
FIRST Teen & Young Adult Zoom Chat
By Meg Mains The GBS-CIDP Foundation International hosted their FIRST Teen & Young Adult Zoom gathering on December 8th. It was a great way to meet other patients and share their experiences with GBS, CIDP, & variant conditions. Meg Mains, Youth, Teen, & Young Adult Team Lead, and Michael Coleman, YTA Spokesperson hosted the virtual…
An Open Letter to Dr. A.S. Fauci, Director NIAID, NIH
(Please see the following open letter statement authored by members of the GBS|CIDP Foundation International medical community as referenced.) As clinician/scientists who have spent careers studying GBS, we are concerned that your statement on the “New Normal” television show about GBS and the COVID vaccine will have unintended consequences. Your statement is already all over…
FDA approved package insert for Pfizer-Biontech COVID-19 vaccine, no mention of GBS as risk
This information is a public document and has been forwarded to the Foundations by our key opinion leaders in the GBS medical community. Of note, there is no mention of GBS in the vaccine insert, not as a risk nor as a vaccine to avoid for those who have had GBS or CIDP or are…
GBS|CIDP Foundation staff & patients collaborate with FDA
By Lisa Butler In 2020 as the Foundation worked with the FDA, for the first time, what I feel is most notable – and praiseworthy – is their straightforward adherence to science, and their tremendous efforts to bring the patient perspective into the decision-making process. I feel even more confident in the leadership of the…
Statement from Professor Lunn in Reference to Newest Research on COVID-19, GBS, and Vaccines
In reaction to recent research published in Brain (click here to read more), Professor Lunn has offered this guidance in regards to our community.
New Study Reveals No Association Between COVID-19 and Guillain-Barré Syndrome
A UK based epidemiological study, linked below, has found no causal association between COVID-19 infection and Guillain-Barré syndrome. This means that GBS developing at the same time or close to that of COVID-19 is most likely coincidental.
Giving Tuesday
GIVE. #givingtuesday December 1, Giving Tuesday, kicks-off the ultimate season of kindness, hope and caring for our global community. A donation to the Foundation is forever appreciated, but there are so many ways to give, big and small. We ask this year, a year that has brought such unprecedented challenges, that you join us, in…
2018 GBS|CIDP Foundation Research Grant Recipient Publishes Update in Journal of Neurology, Neurosurgery & Psychology
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS Principal Investigators: Luana Benedetti, MD, PhD and Lucilla Nobbio, PhD, University of Genova, ITALY CIDP and GBS are immune-mediated neuropathies characterized by strong heterogeneity in terms of clinical manifestations, prognosis and response to treatment. They are treatable diseases and early…
Foundation Hosted Patient Listening Session on Guillain-Barre Syndrome with The FDA
On September 29, 2020, the GBS|CIDP Foundation International organized a patient-led listening session on Guillain-Barre Syndrome (GBS). More than 30 members of various branches within the FDA logged on to the virtual meeting to hear about patients’ experiences with GBS. The FDA’s role was to listen and learn about what life is like during and…
Plasma Please
Plasma is the straw-colored liquid portion of blood that contains proteins that are essential for the human body, including antibodies and clotting factors. Antibodies (also known as immunoglobulins) play an important role in health and illness. Many patients living with CIDP, MMN or Variants regularly receive intravenous immunoglobulin (IVIG) subcutaneous immunoglobulin (SCIG) to treat the…
Building Muscle at Any Age
By Dr. Julie Rowin A publication from Dr. Julie Rowin’s Blog Post found at: julierowinmd.com The benefits of maintaining muscle mass at any age cannot be underestimated.Here’s why: Muscle is involved in brain function in a big way. Muscle directly communicates with the brain through chemicals and messengers such as brain-derived neurotrophic factor (BDNF). These chemicals…
Hey doc, are you sure this is CIDP?
By Jeffrey A. Allen MD,University of Minnesota It’s ok to ask the question. Whether you’ve had the diagnosis for a day or a decade its ok to ask. You should ask. Do my symptoms make sense? Are my test results what you would expect for CIDP? Have other explanations been explored? Should I get a…